From the Journals

NASH rapidly overtaking hepatitis C as cause of liver cancer


 

FROM THE JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY


“Histologically, NASH shares characteristics with alcoholic liver disease, primarily proinflammatory fat accumulation in parenchymal cells, [and] key players in NASH progression to HCC are suggested to include genetic modifications, proinflammatory high-fat and/or high-fructose diets, and oxidative and endoplasmic cellular stresses,” they wrote. “In HCV progression to HCC, the presence of the HCV core protein may induce HCC without the prerequisite load of genetic errors normally required for cancer development, skipping or accelerating some of the classic steps of cancer induction.”

The authors did note that their model represented a base scenario that assumed the environmental and genetic factors driving NASH would continue along the path of current trends.

“Therefore, the possibility exists that our models underestimate the response of the medical community in addressing the rising nonalcoholic fatty liver disease/NASH epidemic.”

No funding sources or conflicts of interest were declared.

SOURCE: Ahmed O et al. J Clin Exp Hepatology. 2018 Feb 24. doi: 10.1016/j.jceh.2018.02.006.

Pages

Recommended Reading

Unrestricted DAA access halved Dutch HCV incidence in HIV
Clinician Reviews
HCV testing stagnant among baby boomers
Clinician Reviews
HCV ‘cure’ within the VA appears likely
Clinician Reviews
Eliminating hepatitis in the United States: A road map
Clinician Reviews
Revaccinate HIV-infected teens with hepatitis B vaccine
Clinician Reviews
Foodborne illnesses of foreign, domestic origin: On the rise?
Clinician Reviews
Hepatitis C is a pediatric disease now
Clinician Reviews
FDA approves new treatment for adults with HCV
Clinician Reviews
AAP recommends hepatitis B vaccine within 24 hours of birth for all infants
Clinician Reviews
HCV infection tied to premature ovarian senescence and a high miscarriage rate
Clinician Reviews